• PDF / 168,851 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 66 Downloads / 162 Views

DOWNLOAD

REPORT

1 S

Intrauterine growth retardation: case report In a retrospective and descriptive study, one woman [age not stated] was described, who developed intrauterine growth retardation during treatment with certolizumab pegol for rheumatoid arthritis [dosage, route and time to reaction onset not stated]. The woman started receiving certolizumab pegol. Subsequently, she conceived. She continued treatment with certolizumab pegol during pregnancy. Subsequently, she presented with intrauterine growth retardation. Ibarguengoitia O, et al. Pregnancy and inflammatory arthropaties: Experience in a multidisciplinary unit. Annals of the Rheumatic Diseases 79 (Suppl. 1): 1874, Jun 2020. 803516430 Available from: URL: http://doi.org/10.1136/annrheumdis-2020-eular.2579 [abstract]

0114-9954/20/1831-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 21 Nov 2020 No. 1831

Recommend Documents

Certolizumab pegol

145 52 180KB

Certolizumab-pegol

135 10 165KB

Certolizumab pegol

130 19 167KB

Certolizumab pegol

132 36 166KB

Certolizumab-pegol

121 46 166KB

Certolizumab pegol

125 28 172KB

Certolizumab pegol

166 76 166KB

Adalimumab/certolizumab-pegol

132 78 166KB

Adalimumab/certolizumab-pegol

127 43 148KB

Adalimumab/certolizumab-pegol/infliximab

130 24 166KB

Adalimumab/certolizumab-pegol/golimumab

140 41 165KB

Infliximab, Golimumab, and Certolizumab Pegol

146 19 10MB